Gregory Ferenstein
Gregory Ferenstein is a senior fellow in drug policy at Reason Foundation.
-
Psychedelics Policy Newsletter: A retail system model, ibogaine research, and legalization updates
A model that would reduce costs and increase consumer access to psychedelics by streamlining the overall regulatory burden.
-
State psychedelics legalization and policy roundup — March 2024
The current state proposals fall into a few broad categories, primarily regulated access and decriminalization of psychedelics.
-
Massachusetts ballot initiative aims to legalize psychedelics
The initiative would legalize guided in-person psychedelic experiences and allow people to grow and consume psychedelics for spiritual or mental health purposes.
-
Nonprofit announces new partnership with Ohio to tackle opioid addiction with ibogaine
A promising new partnership announced in Ohio this week will explore the use of the psychedelic compound ibogaine to treat opioid use disorder.
-
A policy framework for personal psychedelics licenses
Psychedelic licenses for consumers have advantages over the current approach in two U.S. states that rely on professionals to dispense and facilitate services.
-
Psychedelics Policy Newsletter: Impactful ibogaine study, bill introduced in New Hampshire, and more
Plus: State news roundup and the defense spending bill calls for research on using psychedelics to treat PTSD in military members, and more.
-
State psychedelics policy roundup: January 2024 edition
New Hampshire proposes retail sales, Colorado considers ways to lower costs of professional services, and more.
-
New Hampshire proposes a unique approach to medical psychedelics
House Bill 1693 would allow qualified individuals to purchase and consume LSD, mescaline, and psilocybin.
-
New study of psychedelic ibogaine could motivate policy reforms
A recent study could help remove barriers to the development of ibogaine as a promising treatment for opioid addiction.
